Repositioning Candidate Details
| Candidate ID: | R0437 |
| Source ID: | DB05382 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Iodine |
| Synonyms: | |
| Molecular Formula: | I2 |
| SMILES: | II |
| Structure: |
|
| DrugBank Description: | Molecualar iodine has been developed by Symbollon Pharmaceuticals. It is a potential treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia) associated with fibrocystic breast disease (FBD). |
| CAS Number: | 7553-56-2 |
| Molecular Weight: | 253.8089 |
| DrugBank Indication: | Investigated for use/treatment in breast disorders (unspecified) and pain (acute or chronic). |
| DrugBank Pharmacology: | |
| DrugBank MoA: | Molecular iodine is known to inhibit the induction and promotion of N-methyl-n-nitrosourea-induced mammary carcinogenesis, to regress 7,12-dimethylbenz(a)anthracene-induced breast tumors in rats.It has also been shown to have beneficial effects in fibrocystic human breast disease. |
| Targets: | Sodium/iodide cotransporter; NA |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|